Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-10-04
2005-10-04
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S190100, C424S185100, C424S237100, C530S300000, C530S350000, C530S825000, C514S002600
Reexamination Certificate
active
06951653
ABSTRACT:
Novel vaccines for use against β-hemolyticStreptococcuscolonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolyticStreptococcuscolonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
REFERENCES:
patent: 4454121 (1984-06-01), Beachey
patent: 4695562 (1987-09-01), Beachey et al.
patent: 4772584 (1988-09-01), Cleary et al.
patent: 5124153 (1992-06-01), Beachey et al.
patent: 5162226 (1992-11-01), Beachey et al.
patent: 5846547 (1998-12-01), Cleary
patent: 6100380 (2000-08-01), Green et al.
patent: 6270775 (2001-08-01), Cleary
patent: 89/09064 (1989-10-01), None
patent: 93/14198 (1993-07-01), None
patent: 93/21220 (1993-10-01), None
patent: 94/06421 (1994-03-01), None
patent: 94/06465 (1994-03-01), None
patent: 95/28960 (1995-11-01), None
patent: 97/26008 (1996-01-01), None
Houghten et al. Vaccines86, Cold Spring Harbor Laboratory, p. 21-25, 1986.
Lazar et al. Mol. Cellular Biol. 8: 1247-1252, 1988.
Feldman et al. Am. J. Respir. Cell Mol. Biol. 5: 416-423, 1991.
Mitchell et al. Mo. Microbiol. 5: 1883-1888, 1991.
Alexander et al. Mocrob. Pathogen. 24: 167-174, Mar. 1998.
The Concise Encyclopedia: Biochemistry and Molecular Biology, (Ed) Scott TA et al. Third Edition, Walter de Gruyter, New York, p. 489, 1997.
Anderson et al., “Processing, stability, and kinetic parameters of C5a peptidase fromStreptococcus pyogenes,” Eur. J. Biochem. 2002, 269:4839-4851.
Cheng et al., “The Group B Streptococcal C5a Peptidase Is Both a Specific Protease and an Invasin,”Infection and Immunity, May 2002, 70:2408-2413.
Berg, A., et al., “Streptococcal Cysteine Proteinase Releases Biologically Active Fragments of Streptococcal Surface Proteins”,The Journal Of Biological Chemistry, 270(17), 9862-9867, (1995).
Bessen, D., et al., “Influence of Intranasal Immunization with Synthetic Peptides Corresponding to Conserved Epitodes of M Protein on Mucosal Colonization by Group A Streptococci”,Infection and Immunity, 56(10), 2666-2672, (1988).
Bessen, D., et al., “Synthetic Peptide Vaccine Against Mucusal Colonization by Group A Streptococci. I. Protection Against a Heterologous M Serotype with Shared C Repeat Region Epitopes”,J. Immunol, 145(4), 1251-1256, (1990).
Booth, S., et al., “Dapsone Suppresses Integrin-Mediated Neutrophil Adherence Function”,The Journal of Investigative Dermatology, 98(2), 135-140, (1992).
Boyle, M., et al., “Measurement of Leukocyte Chemotaxis in Vivo”,Methods in Enzymology, 162, 101-114, (1988).
Bronze, M., et al., “Epitopes of group A streptococcal M protein that envoke cross-protective local immune responses”,J. Immunol., 148(3), 888-893, (1992).
Bronze, M., et al., “Protective Immunity Evoked by Locally Administered Group A Streptococcal Vaccines in Mice”,J. Immunol., 141(8), 2767-2770, (1988).
Brummer, E., et al., “Immunological Activation of Polymorphonuclear Neutrophilis for Fungal Killing: Studies with Murine Cells and Blastomyces Dermatitidis In Vitro”,Journal of Leukocyte Biology, 36, 505-520, (1984).
Carter, P., et al., “Dissecting the catalytic triad of a serine protease”,Nature, vol. 332, XP002135964, 564-568, (Apr. 7, 1988).
Chen, C.C., et al., “Complete Nucleotide Sequence of the Streptococcal C5A Peptidase Gene ofStreptococcus pyogenes”, The Journal of Bilogical Chemistry, 265(6), 3161-3167, (1990).
Clark, J., et al., “A New Method for Quantitation of Cell-Mediated Immunity in the Mouse”,Journal of the Reticuloendothelial Society, 25(3), 255-267, (1979).
Cleary, P., et al., “A Streptococcal Inactivator of Chemotaxis: A new Virulence Factor Specific to Group A Streptococci”,Recent Advances in Streptococci and Streptococcal Diseases(Y. Kimura, S. Kotami and Y. Shiokawa (ed) . Reedbooks ltd; Berkshire, England, 179-180, (1984).
Cleary, P., et al., “Similarity Between the Group B and A Streptococcal C5a Peptidase Genes”,Infection and Immunity, 60(10), 4239-4244, (1992).
Cleary, P., et al., “Sreptococcal C5a Peptidase is a Highly Specific Endopeptidase”,Infection and Immunity, 60(12), 5219-5223, (1992).
Cleary, P., et al., “Virulent Human Strains of Group G Streptococci Express a C5a Peptidase Enzyme Similar to that Produced by Group A Streptococci”,Infection and Immunity, 59(7), 2305-2310, (Jul. 1991).
Courtney, H.S., et al., “Analysis of the role of M24 Protein in group A Streptococcal adhesion and colonization by use of ‘omega’-interposon mutagenesis”,Infect. Immun., 62(11), 4868-4873, (1994).
Fenderson, P., et al., “Tropomyosin Shares immunology Epitopes with Group A Streptococcal M Proteins”,The Journal of Immunology, 142(7), 2475-2481, (Apr. 1989).
Fischetti, V., “Streptococcal M Protein: Molecular Designn and Biological Behavior”,Clinical Microbiolgy Reviews, 2(3), 285-314, (Jul. 1989).
Fischetti, V.A., et al., “Protection against streptoccal pharyngeal colonization with vaccines composed of M protein conserved regions”,Adv. Exp. Med. Bio., 303, 159-167, (1991).
Fischetti, V.A., et al., “Protection against streptococcal pharyngeal colinization with a vacine: M protein recombinant”,Science, 244, 1487-1490, (1989).
Hill, H., et al., “Group B Streptococci Inhibit the Chemotactic Activity of the Fifth Component of Complement”,The Journal of Immunology, 141(10), 3551-3556, (1988).
Hope-simpson, R., “Streptococcus Pyogenes in the Throat: A study in a small population, 1962-1975”,J. Hyg. Camb., 87, 109-129, (1981).
Ji, Y., et al., “C5a peptidase alters clearance and trafficking of group A streptococci by infected mice”,Infection and Immunity, 64(2), 503-510, (1996).
Ji, Y., et al., “Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A streptococcus”,Infect. Immun., 65(6), 2080-2087, (1997).
Kapur, V., et al., “Vaccination with streptococcal extracellular cysteine protease (interleukin-1B convertase) protects mice against challenge with heterologous group A streptococci”,Microbial. Path., 16(6), 443-450, (1994).
Laemmli, U.K., “Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4”,Nature, 227, 680-685, (1970).
Lee, P., et al., “Quantification and Toxicity of Group A Streptococcal Pyrogenic Exotoxins in an Animal Model of Toxic Shock Syndrome-Like Illness”,Journal of Clinical Microbiology, 27(8), 1890-1892, (1989).
Martin, T., et al., “The Effect of Type-Specific Polysaccharide Capsule on the Clearance of Group B Streptococci from the Lungs of Infant and Adult Rats”,The Journal of Infectious Diseases, 165, 306-314, (1992).
Massell, B., et al., “Rheumatic Fever Following Streptococcal Vaccination”,JAMA, 207(6), 1115-1119, (1969).
Mcghee, J., et al., “New Perspective in Mucosal Immunity with Emphasis on Vaccine Development”,Seminars in Hematology, 30(4)Suppl. 4, pp. 3-15, (Oct. 1993).
Medaglini, D., et al., “Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacteriumStreptococcus gordoniiafter oral colonization”,Proc. Natl. Acad. Sci. USA, 92(15), 6868-6872, (1995).
O'connor, S., et al., “In Vivo Streptococcus Pyogenes C5a Peptidase Activity: Analysis Using Transposon- and Nitrosoguanidine- Induced Mutants”,The Journal of Infectious Diseases, 156(3), 495-504, (1987).
O'connor, S., et al., “The Human Antibody Response to Streptococcal C5a Peptidase”,The Journal of Infection Diseases, 163, 109-116, (1991).
Podbielski, A., et al., “The Group A Streptococcal VirR49 Gene Contr
Cleary Paul Patrick
Stafslien Deborah K.
Devi S.
Fish & Richardson P.C. P.A.
Regents of the University of Minnesota
LandOfFree
Streptococcal C5a peptidase vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Streptococcal C5a peptidase vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Streptococcal C5a peptidase vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3436444